Stematix™ Obtains Exclusive License to Regenexx® Stem Cell Procedure Treating Musculoskeletal Diseases in Latin America
License Strengthens Stematix’s Regenerative Treatments
Houston, TX (PRWEB) October 23, 2009 — Stematix Inc., announced today it has signed an exclusive royalty-bearing license agreement, for the Latin American territory, to use an innovative process that rapidly grows a patients own adult stem cells to treat a variety of musculoskeletal diseases.
Stematix which is establishing international therapy clinics in public-private partnerships to provide near-term and approved stem cell treatments for hundreds of millions of patients that could potentially benefit.
Through its and its partners’ industry know-how and experience, Stematix has developed a suite of commercial products and solutions to help the stem cell research community and also global partners establish world-class stem cell therapy, banks and therapy clinics in a cost-effective and timely manner.
The licensed procedure has been developed by Regenerative Sciences, LLC, a Colorado-based company focused on developing a medical procedure for the treatment of chronic orthopedic conditions. Known under the name Regenexx®, the innovative outpatient procedure takes stem cells from an individual’s bone marrow, isolates mesenchymal stem cells (which can grow into bone, tendon, muscle, ligament and cartilage), cultures them in a solution containing unique elements from the individual’s own blood, and generates millions of stem cells over two to three weeks. These cells are then re-injected into the person’s joints or bones in an office procedure to assist in tissue healing and restoration of bone and cartilage. The Regenexx Procedure has helped many patients avoid more risky and costly surgical intervention.
Additionally, Regenerative Sciences’ founder and CEO, Christopher Centeno, M.D., has agreed to serve as a consultant to Stematix Inc. in the area of stem cell therapy in orthopedics. Dr. Centeno is an international expert in musculoskeletal, spinal and neurological injury. Dr. Centeno will continue to assist Stematix in using mesenchymal stem cell isolation and transplantation methods abroad in the lab and clinical setting. He will also train personnel in Colorado in mesenchymal stem cell isolation, preparation and transplantation methods.
David C. Bonner, Ph.D., Chairman and CEO of Stematix, said, “We at Stematix are excited to be working with Regenexx, the leaders in applied regenerative medicine for orthopedics. We anticipate that this cutting edge, proven treatment will provide needed care for many patients in clinics established in Latin America. We are working toward a first clinic in Argentina during 2010. The expertise and experience of Dr. Centeno and Dr. Schulz will be invaluable in establishing our clinic in Argentina, and we look forward to incorporating advances in the treatment methodology that the Regenexx clinic in Denver will lead. ”
Dr. Centeno said, “I look forward to working with Stematix and their team to bring Regenerative Science’s important stem cell innovations to a worldwide audience of doctors and patients. I’m especially excited about Stematix’s relationships and its expanding presence in Latin America.”
About Stematix™, Inc.
Stematix is a regenerative medicine therapy company poised to accelerate safe and effective use of stem cell therapies globally. Stematix is establishing international therapy clinics in public-private partnerships that provide near-term and approved stem cell treatments for hundreds of millions of patients that could potential benefit. Through industry partnerships, Stematix has developed a suite of commercial products and solutions to help the stem cell research community and also global partners establish word-class stem cell therapy, banks and therapy clinics in a cost-effective and timely manner.
Ms. Timmie Wang, Vice President Business Development
Carl R. Measer, MBA, Chief Operating Officer